Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis New Molecular Entity — NME Approvals by Year
Novartis New Molecular Entity — NME Approvals: 2 in FY2025.
Latest, FY2025
2
Period ended Dec 31, 2025
Change on a year earlier
–
0 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
“| New molecular entity (NME) approvals | 2 | 0”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | New Molecular Entity — NME Approvals | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | – | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 0 | -100.0% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2023 | Dec 31, 2023 | 1 | 0.0% | Novartis Form 6-K (0001370368-25-000008) ↗ |
| FY2022 | Dec 31, 2022 | 1 | -50.0% | Novartis Form 6-K (0001370368-25-000008) ↗ |
| FY2021 | Dec 31, 2021 | 2 | -50.0% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2020 | Dec 31, 2020 | 4 | – | Novartis Form 6-K (0001370368-23-000009) ↗ |
Cite this data
StockData. (2026). Novartis New Molecular Entity — NME Approvals, annual FY2020–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rd-approvals-nme
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.